Tissue Regenix Gets Approval For DermaPure Coding System

LONDON (Alliance News) - Tissue Regenix PLC said Thursday it has received a preliminary positive decision from the Centers for Medicare and Medicaid Services in the US for the assignment of a permanent Healthcare Common Procedure Coding System Q-code for its DermaPure product.

The regenerative medical devices company said the assignment of unique Q-code will enable wound care clinics, ambulatory surgical centres and hospital outpatient facilities located outside the acute care hospitals to apply for reimbursement under Medicare for patients who are treated using DermaPure.

DermaPure works by taking human donor skin and removing the DNA and cells, using the Tissue Regenix-patented dCELL process to leave a natural biological receptive scaffold that can be placed in the wound to aid healing by attracting the patient's own cells to the wound area.

Shares in the medical firm were trading 2.86% higher at 23.4 pence per share Thursday afternoon.

By Alice Attwood; aliceattwood@alliancenews.com; @AliceAtAlliance

Copyright 2014 Alliance News Limited. All Rights Reserved.